JULY-SEPTEMBER Image Copyright: REUTERS/Tim Wimborne Spotlight On... Multiple Sclerosis AWARDED TO THOMSON SCIENT FIC LIMITED

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "JULY-SEPTEMBER 2010. Image Copyright: REUTERS/Tim Wimborne Spotlight On... Multiple Sclerosis AWARDED TO THOMSON SCIENT FIC LIMITED"

Transcription

1 AWARDED TO THOMSON SCIENT FIC LIMITED Image Copyright: REUTERS/Tim Wimborne Spotlight On... Multiple Sclerosis A PHARMA MATTERS report. JULY-SEPTEMBER 2010 Expert therapy area review of the key market players and deals highlights for leading areas of industry investment and development. These insightful reviews are based on the strategic data and insights from Thomson Pharma and Thomson Pharma Partnering Forecast. (THE SCIENTIFIC BUS NESS OF THOMSON REUTERS)

2 Abstract Oral drugs will soon revolutionize treatment of multiple sclerosis. Until recently, the only disease-modifying agents available were the interferons, a highly competitive drug class, but with the disadvantage of administration by injection. This report observes how this key drug franchise is evolving, and evaluates the strengths and weaknesses of the current and future players. Development of the deals landscape during this time of change is discussed, highlighting recent activity as industry heavyweights pair up for commercialization of the leading products, but also make significant investments in developmental candidates that show promise. Extracting consensus data from Thomson Pharma Partnering Forecast, the report assesses the present market and reveals the future dynamics and competitive positioning of therapeutics in this exciting therapy area as it diversifies and transforms. Sales figures are correct as of July 16, 2010 For more information on Thomson Pharma and Thomson Pharma Partnering Forecast visit go.thomsonreuters.com/commercial or

3 SECTION I An evolving multiple sclerosis market: the oral revolution With impending launches of the first oral drugs for multiple sclerosis (MS), the MS market is entering an exciting phase of evolution, which will significantly impact patients lives and transform the competitive landscape of this therapy area. Since 1993, the only disease-modifying options for MS have been a range of interferon-based products, which are administered intravenously, intramuscularly or subcutaneously, typically with considerable discomfort. Competition has been intense between the interferon products, and was compounded by the entry of two new injectable therapies (Copaxone and Tysabri) over the last decade. Competition across the market is now expected to further escalate as the race for the first oral MS drug approval intensifies. According to Thomson Pharma Partnering Forecast, the MS market is set to rise from $8.9 billion in 2008, to $15.6 billion in 2014, based largely on the expected entry of several new oral therapy options, although the beta interferon brands and Tysabri will also see some growth. This rapidly evolving market is also expected to further diversify as companies with no previous involvement enter the sector. The MS market until now has been dominated by an oligopoly; Biogen Idec, Teva, Merck Serono and Bayer Schering have been the leading competitors globally. However, companies like sanofi-aventis, AstraZeneca, Novartis and Glenmark, with some of the most technologically advanced products in their pipeline portfolio, are expected to start to attract the most investor attention as the market begins to change. Indeed, Novartis is employing several strategies to enter the field of MS therapeutics, including in-house development, early- to mid-stage partnering, and development of biosimilars. There has been a significant expansion of the MS market, driven primarily by price increases, new patient diagnoses in the US, and by higher penetration rates in EU markets. MULTIPLE SCLEROSIS WORLDWIDE (US$) 2008 REPORTED SALES Avonex 25% Rebif 22% NATALIZUMAB 9% GLATIRAMER ACETATE 25% Betaseron 19% MULTIPLE SCLEROSIS WORLDWIDE (US$) 2014 CONSENSUS FORECASTS Betaseron 9% Avonex 15% alemtuzumab 2% Rebif 14% NATALIZUMAB 9% GLATIRAMER ACETATE 26% fingolimod 7% FAMPRIDINE (ORAL, sustained release, ms / spinal cord injury, ACORDA/Biogen 6% ExTAvia 2% CLADRIBINE (ORAL, MS), Merck Serono 3% Other 7%

4 There is a demand for oral therapy given the inconvenience of dosing of existing injectable therapies. multiple sclerosis: the current market The MS market has changed very little over the past 10 years. Four injectable disease-modifying drugs monopolized the landscape, with three formulations of beta interferon (Biogen Idec s Avonex, Merck Serono s Rebif, and Bayer/Novartis Betaseron) and one complex immunomodulatory peptide (Teva s Copaxone). Copaxone became the best selling MS drug in 2008, driven primarily by the drug s tolerability and status as the only non-interferon front-line agent. Copaxone gained its dominant market share largely through data from the REGARD and BEYOND trials, which supported efficacy equal to that of the interferons, without the associated tolerability issues. In July 2008, Momenta/Sandoz and Mylan filed ANDAs for Copaxone, which are currently being litigated and could threaten sales going forward. Copaxone is a mixture of chemically synthesized polypeptides, and although not approved as a biologic, because the multiepitopic sequences in Copaxone are not completely characterized, Teva has argued that biosimilar manufacturers will not be able to demonstrate their drug is a precise copy of Copaxone. Although the FDA considers these contentions unpersuasive, Copaxone is not expected to lose its bestseller position until 2013, even as the market starts to radically diversify with the expected entry of oral therapies in Even in the face of this competition, sales for Copaxone are expected to rise from $2.26 billion in 2008 to $3.872 billion in Avonex had been the best-selling MS drug until 2008, but despite being overtaken by Copaxone, it still remains the top-selling interferon, having performed well in the face of competition from the higher-dose interferons. Steady market share and aggressive US pricing are supporting moderate sales growth, and the product is expected to maintain its number one interferon product status to 2013, with sales rising from $2.03 billion in 2008 to $2.342 in In a further effort to support the franchise, Biogen Idec is also developing PEGylated Avonex, which prolongs the drug s halflife and improves its ease of use to twice-monthly injections; phase III trials are ongoing. Despite Avonex s status as the top interferon, Rebif is the fastest-growing interferon product in the franchise. Sales grew 15% in 2008 to $1.958 billion, although the total was impacted by currency. Rebif has benefited from data from the EVIDENCE trial, which established superiority for high-dose Rebif over Avonex over 12 months. According to Thomson Pharma Partnering Forecast, Rebif will see continued strongest growth within the three interferon products in the period up to 2013, rising to $2.183 billion. REPORTED AND CONSENSUS FORECAST REVENUE (MILLION US$) Copaxone Avonex Rebif Betaseron SALES IN US $ YEAR* REPORTED CONSENSUS * Data is derived from Thomson Pharma Partnering Forecast

5 TYSABRI: gaining market share, but PML risk significant In late 2004, Biogen Idec and partner Elan received first approval for Tysabri in the treatment of MS. Seemingly destined for blockbuster status, the drug s commercialization was halted less than three months into its launch following two cases of severe progressive multifocal leukoencephalopathy (PML) reported in clinical trial patients treated with a combination of Tysabri and Avonex for more than two years. A third confirmed case was then reported in a Crohn s disease patient receiving intermittent Tysabri monotherapy over 18 months. At that time, Biogen Idec and Elan completed a full review of Tysabri s safety throughout its entire clinical trial program and found no additional cases of PML in 3000 patients who had received the drug. Tysabri remained withdrawn from the market until further analyses had been presented to the FDA, at which point a positive FDA panel recommendation led to its relaunch in the US in July 2006, under the TOUCH risk management program. The FDA had reviewed the impressive efficacy data for Tysabri, and concluded the risk/benefit was acceptable when other therapies had failed. The drug s approval was based upon data from the AFFIRM (Tysabri monotherapy versus placebo) and SENTINEL (Tysabri plus Avonex combination versus Avonex) studies. In these trials, Tysabri induced a dramatic reduction in relapse rate versus either placebo or Avonex monotherapy. In AFFIRM, patients experienced a 66% reduction in relapse rates after one year, with annualized relapse rates of 0.25 for Tysabri versus 0.74 on placebo. At two years, AFFIRM demonstrated a 42% reduction in the risk of disability progression for the Tysabri treatment arm versus placebo, eclipsing reported risk reductions for Avonex (37% reduction) and Rebif (30% reduction), while Betaseron and Copaxone have never shown an impact on disease progression. Since its relaunch, Tysabri has steadily gained market share, and the drug surpassed $1 billion in sales for the first time in By June 2010, regulators had linked the drug to 11 deaths and 55 cases of PML since it was reintroduced in 2006, although were still recommending it remain on the market. However, the drug s sales will inevitably be closely linked to its rate of association with PML, and another 12 months of commercial experience may be required before Tysabri s true association with PML becomes clearer, possibly with data from the TYGRIS trial. In the meantime, Biogen Idec is evaluating whether earlier diagnosis followed by plasma exchange might improve patient outcomes, and is also seeking to identify factors that might predispose certain patients to PML. Sales are forecast to rise from $831 million in 2008 to $1.517 billion in 2013, according to Thomson Pharma Partnering Forecast, which could be its peak year of sales. Avonex, with its convenient dosing and lower side effects, may benefit from a large-scale phase III trial examining the combined use of Avonex and Copaxone that is due to complete in July 2012.

6 Rebif is clinically superior to Avonex after 24 weeks, despite being chemically identical, according to data from the EVIDENCE trial. These data allowed the drug to gain FDA approval, despite Avonex holding Orphan Drug exclusivity. The first oral THERAPIES Despite the relative lack of options for MS over the last decade, significant research is ongoing into newer targeted immune therapies for MS, including the monoclonal antibodies daclizumab, alemtuzumab and ocrelizumab, and the T-cell vaccine Tovaxin. However, it is the success in trials of the oral MS therapies which has created the greatest excitement among investors, and it is these which are the most anticipated new treatment options. Merck Serono s cladribine (Mylinax) and Novartis s fingolimod (FTY- 720), both in regulatory filing, and sanofi-aventis s teriflunomide, Biogen Idec s BG-12, and Active Biotech s laquinimod, all currently in phase III development, are the most keenly watched oral pipeline products. These are at the most advanced stages of development, and have demonstrated induction of remyelination, reduction in lesions and relapses, and reduced side effects. Between the two most advanced drugs, Novartis has edged ahead of Merck Serono in the race to get the first oral MS treatment to market, having now filed for approval of fingolimod in the US and Europe. The FDA will conduct a priority six-month review, which could bring it to market by year-end. Merck Serono filed its US application for cladribine first, in September 2009, but the FDA rejected the filing two months later as incomplete, which means that although the filing was resubmitted in June 2010, Novartis will most likely be the first company to get an oral therapy registered in the US with fingolimod. Fingolimod: strong efficacy but concerning side effects Novartis filed fingolimod for approval at the lowest dose studied in trials (0.5 mg), which had the best benefit-risk profile. Data published from two late-stage trials have showed fingolimod is effective in reducing relapses, disability progression and lesions. In the one-year TRANSFORMS study, involving 1292 patients, the lower dose of fingolimod reduced relapses by more than 50% compared with Avonex. Robust efficacy was also confirmed by the FREEDOMS study, in which fingolimod (1.25 mg) reduced the relapse rate by 60% compared with placebo. However, questions about the tolerability of fingolimod persist. While efficacy appeared impressive in TRANSFORMS, the trial highlighted a potentially concerning side-effect profile. There were two fatal herpes infections, and one death from a progressive neurological condition of unclear etiology. While the lower dose appeared to be associated with less risk of infection, opportunistic infections were still observed in this relatively short-term study. Almost as concerning was that eight patients on fingolimod (six on the low dose, two on the high dose) developed melanoma and two developed breast cancer. Transient reductions in heart rate, increases in blood pressure (1 to 3 mmhg), elevations in liver enzymes, and increased rates of macular edema were also seen in fingolimod-treated patients. As long as these side effects do not worsen with time, it is anticipated that physicians and patients may be willing to accept the risks, given the significant demand for oral dosing, and sales are forecast to ramp quickly upon launch, reaching $853.7 million in Nonetheless, the threat to the existing major players in the franchise may be somewhat tempered by the need for a stringent risk evaluation and mitigation strategies (REMS) program involving a broad group of specialty physicians.

7 Mylinax prolonged lymphopenia MAY be an issue Oral cladribine (Mylinax) is a new formulation of the intravenous chemotherapeutic cladribine, currently approved for the treatment of hairy cell leukemia. Positive data from the phase III CLARITY trial showed a 58% reduction in relapse rate over two years with Mylinax treatment, which while not as great as the reductions seen with Tysabri, place it above the first-line interferons. However, the reduction in disability associated with Mylinax (33%) in CLARITY did not quite match reductions seen with Avonex (37%) and Tysabri (42%+), although reductions in lesion activity were evident. As with fingolimod, the biggest question at this stage is cladribine s safety profile and its potential to cause elevated incidences of infection. The drug works by causing moderate-to-severe prolonged lymphopenia, the longerterm consequences of which are unclear. In addition, CLARITY featured four cases of cancer and one death from tuberculosis possibly related to the drug. There may also be some question over whether the drug is suitable for use in women of childbearing age. On the positive side, cladribine is viewed as easy to use (as few as 10 days dosing per year), relatively well tolerated, and strongly efficacious. Should the clinical sequelae associated with lymphopenia be manageable, oral cladribine could become a first-line drug with strong clinical potential; sales are forecast to reach $358.7million in Tysabri displays very low rates of relapse with radiographic progression in the real-world setting. REPORTED AND CONSENSUS FORECAST REVENUE (MILLION US$) Mylinax Fingolimod SALES IN US $ YEAR* REPORTED SALES * Data is derived from Thomson Pharma Partnering Forecast

8 Fingolimod s oral convenience may be offset by demands for multidisciplinary monitoring, including liver, dermatology and infection screening. Further ALONG the oral pipeline Sanofi-aventis s teriflunomide is a pyrimidine synthesis inhibitor with immunomodulatory properties. Development has been protracted, with the initial phase III trials beginning in September 2004, first as a monotherapy and then in combination with interferon. Phase II data have been positive, with reductions seen in MRI lesions, and a trend towards reduced disability/ number of relapses. However, some degree of immunosuppression was seen in 49% of patients. The first phase III data, from the TEMSO study, are expected in 4Q10. Biogen Idec s oral second-generation fumarate derivative BG-12 has completed a 257-patient European phase II dose-ranging trial; data showed that the drug reduced brain lesion activity at six months versus placebo; the highest dose (720 mg) reduced the mean number of lesions by 69% between weeks 12 and 24 and led to a 48% reduction in newly enlarging T2-hyperintense lesions. There was a trend toward reduction in relapse rate (32% reduction versus placebo), although this was not significant. While liver enzyme elevations were observed in 2 to 8% of patients, no opportunistic infections occurred in patients on BG-12. Two phase III studies, DEFINE and CONFIRM, have completed enrollment. Teva s laquinimod has received fast-track status from the FDA, and the company believes it could enter the market as soon as late However, so far, phase II data have suggested only modest efficacy. Two phase III trials have completed enrollment. Looking to earlier-stage drugs, Tysabri has validated blockade of the alpha4-β 1 integrins as a therapeutic approach for the treatment of MS, and a number of alpha4 integrins are now progressing through trials, including GlaxoSmithKline s firategrast (licensed from Tanabe in December 2000); a Biogen Idec molecule (CDP-323), part of a collaborative global deal with UCB signed in October 2006, with the same mechanism of action was discontinued in 2009 due to lack of efficacy. AdJUNCTIve THERAPY Effective oral disease-modifying agents for MS will address the treatment goal of preventing long-term disability, and their arrival will herald a sea change in treatment of the disease. However, the scope for oral treatment has not stopped there, and effective symptom management for MS may mark another radical change in the dynamics of the market. The first of these treatment options, Acorda Therapeutics sustained-release fampridine (Ampyra), was approved in January 2010 to improve walking ability in patients with MS; launch took place in March Ampyra successfully completed two SPA-supported phase III trials, which included patients with primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing disease. The first study yielded results in 2006; data were strong, and Ampyra met all three predefined efficacy hurdles. Compared to placebo, a greater proportion of patients on Ampyra showed a consistent improvement in walking speed and were classified as responders, the study s primary outcome (34.8% versus 8.3%). This effect was maintained throughout the 14-week treatment period, and there was a significant improvement in the 12-Item MS Walking Scale for responders versus non-responders. In June 2008, Acorda reported positive data from a further phase III trial, in which Ampyra demonstrated a consistent increase in walking speed across all types of MS. The trial s primary endpoint was met convincingly, with 42.9% of Ampyra patients responding to therapy versus 9.3% on placebo. The average increase in walking speed over the 8 weeks of treatment compared to baseline was 24.7% for the responders compared to 7.7% for placebo.

9 However, despite favorable efficacy data, prescriptions may be limited by price concerns, given that the drug is likely to be prescribed alongside the high-cost disease-modifying agents. Additionally, a dose-related risk of seizures was observed in trials, which could further temper sales. Ampyra addresses an important need in terms of reducing symptoms and consequently the drug is expected to reach sales of $639.6 million in SECTION II deals Highlights The impact of the economic downturn has dramatically influenced the focus and needs of pharmaceutical companies in recent months. As the financial markets show early signs of a slow recovery, licensing activity between companies has been unpredictable but still prevalent and in some cases, profitable. It is clear that the emphasis on ensuring a signed deal sustains longevity is rooted at the relationship between companies. The increased attendance at annual partnering conferences has been a well-observed trend. Thus, confirming that business development representatives understand the need to identify potential partners with expertise and knowledge within a niche field and/or territory, in order to achieve the ideal partnering model of sustainable agreements and pioneer novel therapeutics. The major companies in the MS market that have emerged as prominent deal-making figures include Biogen Idec, Merck Serono and Teva Pharmaceutical. It is important to note that the concurrent licensing activity conducted by these parties also emphasizes the competitive need to maintain partnered agreements. Biogen Idec: a favored partner for multiple SCLEROSIS THERAPEUTICS Biogen Idec became the exclusive non-us partner for the development of Acorda Therapeutics Ampyra in July 2009 (see Table 1). This late-stage deal exemplifies a company realizing the commercialization capabilities of an established major player in the worldwide MS therapy market. While the drug is not expected to achieve blockbuster status, its significant potential was realized by Biogen. As such, the parties agreed to a cost-sharing arrangement, with Biogen committing a large upfront payment of $110 million, regulatory and sales-based milestone payments of up to $400 million and double-digit royalties on ex-us sales to Acorda. By December 2009, Biogen expected to receive an additional payment of $45 million in expenses. Incidentally, Acorda will grant a proportion (7%) of those payments to the drug s originator, Elan. This was significant, considering that during 3Q09, Elan and Biogen were locked in a separate legal dispute regarding blockbuster drug Tysabri. Elan and Biogen had been collaborating on the program (originally developed by Elan) since August 2000, as part of a deal worth over $125 million (see Table 1). However, Biogen claimed Elan had breached contract by signing a Strategic Financing and Collaboration Agreement related to the drug with a Johnson & Johnson (J&J) affiliate. In September 2009, the United States District Court for the Southern District of New York ruled in favor of Biogen s claim and Elan terminated the relevant portion of its transaction with J&J. Despite this unintentional breach, it was clear that the market clout of Biogen proved to be too valuable an asset to lose. The companies continue to collaborate under a cost/profit-sharing arrangement, with no additional milestone payments required; for the year ending December 31, 2009, $215.9 million was reflected in the two collaborators recorded profit-sharing line for Tysabri. We believe that Biogen Idec s international expertise in MS and neurology also will help us optimize future development of Ampyra and maximize its value in markets outside the US. Ron Cohen, MD, President and CEO of Acorda

10 Biogen demonstrated its aptitude in the MS arena after acquiring BG-12 (dimethyl fumarate) from Swiss firm Fumapharm in October 2003 (see Table 1); the company was acquired by Biogen in July The drug was originally developed for the potential treatment of psoriasis, reaching phase III of development. However, the partners had agreed to withdraw a marketing authorization application for psoriasis in Germany by September Given the strength of BG-12 s anti-autoimmune activity, Biogen continued to pursue the program for MS and rheumatoid arthritis (RA). Enrollment of a phase III trial involving 1237 patients was completed in March DRUG fampridine (Ampyra) natalizumab (Tysabri) dimethyl fumarate (BG-12) PARTNER COMPANY Acorda Therapeutics DEAL START DATE July 2009 DEAL VALUE (US $)* 510 million (plus royalties) Elan August million (plus royalties) Fumapharm October 2003 Undisclosed Table 1: Summary of Biogen Idec s MS-related development and COMMERCIALIZATION AGREEMENTS * Approximate values based on the achievement of all milestones for the principal components included in the deal. Biogen finds marketing partners for Avonex Biogen has a widely recognized marketing and distribution network for its recombinant interferon β-1a based program Avonex, including Latin American, Australian, Indian and Nepal, Spain and Nordic regions. The drug, originally formulated using Inhance drug delivery technology licensed from Nektar Therapeutics, is marketed by Abbott Laboratories in Latin American countries, CSL in Australia, Piramal Healthcare in India and Nepal, and distributed by AstraZeneca in Nordic regions and Schering- Plough in Spain (see Table 2). PARTNER COMPANY DEAL START DATE TERRITORIES COVERED Abbott Laboratories February 1998 Latin America CSL June 1999 Australia Piramal Healthcare December 2003 India and Nepal AstraZeneca August 1996 Nordic region (distribution only) Schering-Plough (distribution only) August 1996 Spain Table 2: Summary of Biogen Idec s marketing and distribution DEALS for Avonex Merck Serono develops competitor product TO Avonex Merck KGaA s subsidiary Merck Serono has developed Rebif, another recombinant interferon β-1a, which was launched in the US in March 2002 after demonstrating superiority to Avonex. Both were designated Orphan Drug Status for fast-track approval. However, at the time, the FDA informed Biogen that the drug s approval letter specifically prohibited labeling with broad claims of clinical superiority. Merck Serono originally licensed rights to the drug from the Weizmann Institute of Science (see Table 3). Following its US launch, Merck Serono enlisted the commercial weight of pharma giant Pfizer to copromote Rebif. The drug is also comarketed in Italy with Italfarmaco, under an agreement signed in 1992 with Ares-Serono (see Table 3).

11 Merck Serono and Teva join forces AGAINST MULTIPLE sclerosis Merck Serono is also developing Mylinax (oral cladribine), licensed on a worldwide basis from IVAX in October 2002 (see Table 3). Following Teva s acquisition of IVAX in January 2006, Teva decided to discontinue its developmental involvement but continue to offer financial support to the Merck Serono-led program. IVAX exclusively licensed oral and intravenous formulations of the drug from Scripps Research Institute in December 2000, following Scripps demonstration of the candidate s ability to eliminate brain lesions normally associated with MS observed from patient magnetic resonance imaging (MRI) scans. DRUG Recombinant interferon β-1a (Rebif) Recombinant interferon β-1a (Rebif) Recombinant interferon β-1a (Rebif) cladribine (oral; Mylinax) PARTNER COMPANY Weizmann Institute of Science Pfizer Italfarmaco Teva Pharmaceutical TYPE OF DEAL Development/ commercialization worldwide Copromotion in the US Comarketing in Italy Development/ commercialization worldwide DEAL START DATE By December 1992 July 2002 By December 1992 October 2002 DEAL VALUE (US $)* Undisclosed Undisclosed Undisclosed Undisclosed milestone and royalty payments Table 3: Summary of Merck Serono s major MS-related AGREEMENTS * Approximate values based on the achievement of all milestones for the principal components included in the deal. Teva s major multiple sclerosis deals Teva s non-interferon-based MS therapy Copaxone has been launched in the US since The active compound was discovered at the Weizmann Institute of Science and subsequently licensed to Teva for commercial development. While Teva retained the majority of MS development rights, the company was comarketing the drug in the US with Marion Merrell Dow (MMD), through the joint venture Teva Marion Partners. In December 1995, Teva outlicensed worldwide (excluding the US) marketing rights to French conglomerate sanofi-aventis. Teva acquired sanofi-aventis stake in the joint venture in February 2001; sanofi-aventis continued to receive revenues from North American sales until March 2008, when Teva reacquired North American distribution rights. Currently, Teva and sanofi-aventis continue to jointly commercialize the drug in major European markets. The two parties copromote the drug in Germany, UK, France, Spain, Netherlands and Belgium. sanofi-aventis has sole marketing rights in other European markets, as well as Australia and New Zealand (see Table 4). It was reported that Teva is in the process of reacquiring rights to all territories by the first quarter of 2012, effectively terminating the agreement; sanofi-aventis would be eligible to receive predetermined termination payments in the meantime. Finally, one of Teva s most lucrative licensing agreements in the MS arena stems from its June 2004 deal with Swedish firm Active Biotech for its phase III autoimmune suppressant laquinimod. The original deal, in which After working with Teva since 2004 on developing laquinimod we believe that Teva is the optimal marketing and distribution partner in our territory. Tomas Leanderson, President & CEO, Active Biotech

12 Active Biotech could earn up to $97 million in upfront and milestone payments plus royalties, granted Teva exclusive rights to develop, register and commercialize the candidate worldwide (excluding Nordic and Baltic regions). These terms were amended in February of this year, granting Teva Nordic and Baltic territory rights. Active Biotech agreed to receive a higher royalty rate on eventual sales of the drug (see Table 4). DRUG glatiramer acetate (Copaxone) laquinimod (SAIK-MS) PARTNER COMPANY sanofiaventis Active Biotech TYPE OF DEAL Comarketing in Europe Marketing in Australia/ New Zealand Development/ commercialization worldwide DEAL START DATE January 1996 June 2004 DEAL VALUE (US $)* Undisclosed 97 million (plus royalties) Table 4: Summary of Teva Pharmaceutical s major MS-related AGREEMENTS * Approximate values based on the achievement of all milestones for the principal components included in the deal. Summary While the ultimate goal of neuroprotection and repair of damaged areas of the nervous system remains distant, the addition of new agents to an interferon or Copaxone backbone may enhance efficacy. However, the true blockbuster potential lies with a safe and effective oral agent, which will constitute a new platform therapy. The avoidance of injections and potentially greater tolerability may also lead to significant increases in the number of patients with MS who begin and remain on treatment, thus expanding the market. So far, licensing activity surrounding MS therapeutics with promising scientific backing has borne several deals individually worth more than $100 million, and the future also appears solid. At the R&D end of the spectrum, novel animal disease models are being evaluated and companies are collaborating on the development of several promising next-generation candidates: Merck Serono is investigating orally active tetracycline derivatives, as part of a development deal with Paratek, and Teva has partnered with Vaccinex on the development of the human monoclonal antibody vx-15, which Teva is investigating for MS. Lastly, using Dyax s proprietary phage display technology, a demyelinating disease program targeting the Nogo-66 receptor/p75 signaling complex was discovered from a long-standing collaboration between Biogen and Dyax. The strategic partnering activity in the market also indicates that not all pharma companies are collaborating with the well-known major players. Instead, some firms are actively seeking partners with specific experience and an established commercial strength. The prospect of potentially novel oral MS therapeutics also heightens the necessity to utilize companies specific formulation expertise. These first oral therapies are likely to be offered in the very near future, although physicians will begin to use these without long-term plans for their use, and careful monitoring of the longer-term effects of more effective immunomodulation will be required. However, in a decade from now, there could be ten or more oral therapeutic options for MS, and the revolution in the treatment of this enigmatic disease may be complete.

13 NOTES

14 THOMSON PHARMA World LEAding PHARMACEUTICAL COMPETITOR intelligence SOLUTION Image Copyright: REUTERS/Enrique Marcarian Thomson Pharma gives you the freedom to explore the best pharmaceutical content from the extensive collection of intellectual property, scientific, healthcare and financial information databases offered by Thomson Reuters. This critical market intelligence is enhanced and placed in context with unique abstracts, summaries, commentaries and analysis prepared by our team of industry experts. No other data source puts so much information at your fingertips. For more information visit go.thomsonreuters.com/thomsonpharma AWARDED TO THOMSON SCIENTIFIC LIMITED (THE SCIENTIFIC BUSINESS OF THOMSON REUTERS)

15 Thomson Pharma Partnering FORECAST CREDIBLE DATA FOR CREATING QUALITY SALES FORECASTS Image Copyright: istockphoto Thomson Pharma Partnering Forecast offers both market-based consensus analyst forecasts and transparent patient-based forecasts along with drug summaries from Thomson Pharma s trusted pipeline database. Review and adjust with your own assumptions to quickly generate your own forecasts. For more information visit go.thomsonreuters.com/forecast 2010 Thomson Reuters. All rights reserved. Thomson Reuters and the Kinesis logo are trademarks of Thomson Reuters.

16 To sign up to our Pharma Matters range of publications visit: go.thomsonreuters.com/pharmamatters THE ONES TO WATCH Focuses on the latest phase changes in the pharmaceutical pipeline. SPOTLIGHT ON Snapshot of the current market players and deals being done in a certain therapy area. MOVERS AND SHAKERS Unravels the most significant game-play in the US generics market. THE CUTTING EDGE OF CHEMISTRY Insights into the chemistry advances transforming drug discovery and development. About Thomson Pharma Thomson Pharma brings together the best pharmaceutical data owned by Thomson Reuters in a single comprehensive solution containing millions of pieces of information. And it s not just data. Thomson Pharma extends and deepens its knowledge with unique abstracts, commentaries and analysis prepared by our team of industry experts. You can link at a click between different types of content. No other data source puts so much information at your fingertips. In place of your legacy indexing systems, multiple interfaces, and complex data sources, imagine how Thomson Pharma can simplify your information needs, justify and speed your decision-making, and keep you abreast of the market. About Thomson Pharma PARTNERING FORECAST Thomson Pharma Partnering Forecast gives you the most accurate available method of assessing the sales potential of new drugs by integrating and summarizing multiple perspectives on drugs that will compete with yours. For each therapeutic franchise, Thomson Pharma Partnering Forecast enables you to compare the most significant candidates in the development pipeline and the key drugs that have reached the market. It provides a consensus of analyst forecasts for pipeline and marketed drugs, and downloadable, patient-based revenue models for drugs in more than 100 indications, providing transparent assumptions on incidence and prevalence, eligible numbers of patients, estimated timing of approval, pricing, and market share within the indication. In addition to proprietary revenue forecasts, catalysts and likelihood of approvals are provided through a partnership with BioMedTracker. About Thomson Reuters Thomson Reuters is the leading source of intelligent information for professionals around the world. Our customers are knowledge workers in key sectors of the global economy. We supply them with the intelligent information they need to succeed in fields that are vital to developed and emerging economies such as law, financial services, tax and accounting, healthcare, science and media. Our knowledge and information is essential for drug companies to discover new drugs and get them to market faster, for researchers to find relevant papers and know what s newly published in their subject, and for businesses to optimize their intellectual property and find competitive intelligence. Healthcare & Science Regional Offices North America Philadelphia Latin America Brazil Other countries Europe, Middle East and Africa London Note TO press: To request further information or permission to reproduce content from this report, please contact: Paul Sandell Phone: For more information on Thomson Pharma and Thomson Pharma Partnering Forecast visit: go.thomsonreuters.com/commercial or Asia Pacific Singapore Tokyo For a complete office list visit: science.thomsonreuters.com/contact PH Copyright 2010 Thomson Reuters

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Multiple Sclerosis Drug Discoveries - What the Future Holds

Multiple Sclerosis Drug Discoveries - What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

A blood sample will be collected annually for up to 2 years for JCV antibody testing. Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

What is Multiple Sclerosis? Gener al information

What is Multiple Sclerosis? Gener al information What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal

More information

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013 Multiple Sclerosis Global Drug Forecast and Market Analysis to 2022 Event-Driven Update GDHC34PIDR / Published April 2013 Executive Summary The table below presents the key metrics for multiple sclerosis

More information

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

New Treatment Options for MS Patients: Understanding risks versus benefits

New Treatment Options for MS Patients: Understanding risks versus benefits New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

The MS Disease- Modifying Drugs. Gener al information

The MS Disease- Modifying Drugs. Gener al information The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please

More information

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

Uncertainty in Benefit and Risk: Tysabri (natalizumab)

Uncertainty in Benefit and Risk: Tysabri (natalizumab) Uncertainty in Benefit and Risk: Tysabri (natalizumab) Robert J. Temple, M.D. Deputy Center Director for Clinical Science Center for Drug Evaluation and Research U.S. Food and Drug Administration IOM Drug

More information

Integrating New Treatments: A Case Based Approach

Integrating New Treatments: A Case Based Approach Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Building on Leading Market Positions

Building on Leading Market Positions Building on Leading Market Positions Bharat Tewarie Head of Global Business Franchise Neurodegenerative Diseases Darmstadt, May 15, 2012 Agenda 1. Introduction 2. Rebif: Defending the franchise 3. Fertility:

More information

Progress in MS: Current and Emerging Therapies

Progress in MS: Current and Emerging Therapies Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the

More information

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

How to S.E.A.R.C.H. SM for the Right MS Therapy For You! How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration

More information

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011 Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

More information

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the

More information

A neurologist would assess your eligibility and suitability for the DMTs.

A neurologist would assess your eligibility and suitability for the DMTs. Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

More information

Global Multiple Sclerosis Drugs Market 2014-2018

Global Multiple Sclerosis Drugs Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/2925806/ Global Multiple Sclerosis Drugs Market 2014-2018 Description: About Multiple Sclerosis and Disease Types Multiple sclerosis

More information

Resources for the Primary Care Provider. Please print these out for reference

Resources for the Primary Care Provider. Please print these out for reference Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health

More information

Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be

More information

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

Natalizumab (Tysabri)

Natalizumab (Tysabri) Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

The MS Disease- Modifying Medications GENERAL INFORMATION

The MS Disease- Modifying Medications GENERAL INFORMATION The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 10/01/2013 10/1/2015 08/25/2015 Policy Name Policy Number Multiple Sclerosis Therapy Class SRx-0022

More information

Resources for the Patient. Please print these out and give them to your patients with MS

Resources for the Patient. Please print these out and give them to your patients with MS Resources for the Patient Please print these out and give them to your patients with MS An internet program for persons with MS on the FCM website Multiple Sclerosis: A Toolbox of Information and Resources

More information

Personalised Medicine in MS

Personalised Medicine in MS Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective

More information

J.P. Morgan Cazenove Therapeutic Seminar

J.P. Morgan Cazenove Therapeutic Seminar Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private

More information

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical

More information

The MS Disease- Modifying Medications

The MS Disease- Modifying Medications The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,

More information

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone ) Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity

More information

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013 National Multiple Sclerosis Society Disease Modification in Multiple Sclerosis Current as of January 2, 2013 Since 1993, the U.S. Food and Drug Administration (FDA) has approved several medications for

More information

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective

More information

1. Comparative effectiveness of alemtuzumab

1. Comparative effectiveness of alemtuzumab Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Understanding How Existing and Emerging MS Therapies Work

Understanding How Existing and Emerging MS Therapies Work Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of

More information

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active

More information

Study Support Materials Cover Sheet

Study Support Materials Cover Sheet Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information

More information

New treatments in MS What s here and what s nearly here

New treatments in MS What s here and what s nearly here 5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability

More information

The submission positioned dimethyl fumarate as a first-line treatment option.

The submission positioned dimethyl fumarate as a first-line treatment option. Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an

More information

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif - PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with

More information

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To

More information

The MS Disease- Modifying Medications

The MS Disease- Modifying Medications The MS Disease- Modifying Medications National MS Society 1 Current as of January 2015. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,

More information

How to S.E.A.R.C.H. for the Right MS Therapy for You!

How to S.E.A.R.C.H. for the Right MS Therapy for You! How to S.E.A.R.C.H. for the Right MS Therapy for You! How to S.E.A.R.C.H. for the Right MS Therapy for You! Copyright Multiple Sclerosis Association of America, 2012. All rights reserved. This booklet

More information

Treatments-related side effects

Treatments-related side effects Treatments-related side effects MS: from the diagnosis to the disease management MSc, MD, José Flores Rivera Instituto Nacional de Neurología y Neurocirugía Safety issues: beta interferon Depression/suicidal

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Relapsing-remitting multiple sclerosis Ambulatory with or without aid AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date

More information

Laquinimod Polman, C. et al. Neurology 2005;64:987-991

Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks

More information

The High Prices of Prescription Drugs Increase Costs for Everyone

The High Prices of Prescription Drugs Increase Costs for Everyone The High Prices of Prescription Drugs Increase Costs for Everyone Individuals, Families, States, Taxpayers All Face Higher Costs Due to Rising Drug Prices Prescription drugs are one of the major drivers

More information

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Information About Medicines for Multiple Sclerosis

Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain

More information

Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or

Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec

More information

There are currently 4 US Food and Drug

There are currently 4 US Food and Drug DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting

More information

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Which injectable medication should I take for relapsing-remitting multiple sclerosis? Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

More information

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease

More information

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Disease Modifying Therapies (DMTs) in Multiple Sclerosis Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of

More information

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15 PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man

More information

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority

More information

Patient Group Input to CADTH

Patient Group Input to CADTH Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

Multiple Sclerosis (MS) Class Update

Multiple Sclerosis (MS) Class Update Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Multiple Sclerosis (MS) Class Update Month/Year of

More information

Disease modifying drug therapy. what you need to know

Disease modifying drug therapy. what you need to know Disease modifying drug therapy what you need to know Contact information Neurologist s name: Neurologist s secretary: Telephone number: MS specialist nurse: Telephone number: Manufacturer helpline number:

More information

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal A Case for Cure: Drug Portfolio Analysis Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal Executive Summary Our team recommends. A Recombinant Protein for treatment of Multiple

More information

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has

More information

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability

More information

TYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc

TYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment

More information

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with

More information

this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director

this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director r STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v File No. 143525-001 Health Alliance Plan of Michigan,

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Clinical Trials of Disease Modifying Treatments

Clinical Trials of Disease Modifying Treatments MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary

More information

Published by MSAA in March 2013

Published by MSAA in March 2013 Published by MSAA in March 2013 Improving Lives Today! MSAA s MS Research Update is published annually as a service to the MS community. For additional information about MS as well as MSAA s programs and

More information